Interestingly, monoclonal antibodies and small-molecule inhibitors targeting CSF1R have been reported to result in a decreased number of TAMs and an increased ratio of CD8+/CD4+ T cells in the tumor (9, 202). Here, CSF1R is linked to neoplasm.